1
Soo S Ko, Richard G Wilde, Indawati DeLucca, Hui Yin Li, Hollis S Kezar III, George A Boswell, Anurag S Srivastava: Amides for the treatment of atherosclerosis. The Dupont Merck Pharmaceutical Company, December 10, 1996: US05583147 (24 worldwide citation)

This invention provides amide compounds as inhibitors of acyl-Coenzyme A: cholesterol O-acyltransferase (ACAT), pharmaceutical compositions containing such compounds, processes for the preparation of such compounds, and the use of such compounds as antihypercholesterolemic and/or antiatherosclerotic ...


2
James D Rodgers, Hui Yin Li: Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. Incyte Corporation, Lathrop & Gage, Brian C Trinque, May 13, 2014: US08722693 (22 worldwide citation)

The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, imm ...


3
James D Rodgers, Hui Yin Li: Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. Incyte Corporation, Lathrop & Gage, Brian C Trinque, September 9, 2014: US08829013 (20 worldwide citation)

The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, imm ...


4
Yun Long Li, Andrew P Combs, Eddy W Yue, Hui Yin Li: Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors. Incyte Corporation, Fish & Richardson P C, March 25, 2014: US08680108 (14 worldwide citation)

The present invention provides fused aryl and heteroaryl derivatives of Formula I: wherein X, V, Y, U, W, Z, R1, R2, Cy, and Ar are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, ...


5
Jiacheng Zhou, Pasquale N Confalone, Hui Yin Li, Philip Ma, Lynette M Oh, Lucius T Rossano, Charles G Clark, Chris Teleha: Efficient ligand-mediated Ullmann coupling of anilines and azoles. Bristol Myers Squibb Pharma Company, David H Vance, April 1, 2003: US06541639 (13 worldwide citation)

The present invention provides of method of preparing phenyl-substituted azoles. This method uses an efficient ligand-accelerated Ullmann coupling reaction of anilines with azoles. The coupling products are useful for preparing factor Xa inhibitors.


6
Jiacheng Zhou, Lynette M Oh, Philip Ma, Hui Yin Li, Pasquale Confalone: Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones. Bristol Myers Squibb Company, Jing G Sun, David H Vance, December 26, 2006: US07153960 (12 worldwide citation)

A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.


7
Hui Yin Li, Andrea Jane Robinson: Asymmetric synthesis of R and S warfarin and its analogs. The DuPont Merck Pharmaceutical Company, David H Vance, November 11, 1997: US05686631 (12 worldwide citation)

The present invention provides a novel process for making compounds of formula 2a or 2b or pharmaceutically acceptable salts thereof, ##STR1## wherein R1 is selected from the group consisting of phenyl and phenyl substituted with at least one group selected from NO.sub.2 and halogen;


8
Jiacheng Zhou, Lynette M Oh, Philip Ma, Hui Yin Li, Pasquale Confalone: Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones. Bristol Myers Squibb Company, Jing G Sun, David H Vance, July 19, 2005: US06919451 (11 worldwide citation)

A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.


9
Hui Yin Li, Andrea Jane Robinson: Asymmetric R and S warfarin and its analogs. DuPont Pharmaceuticals Company, David H Vance, January 5, 1999: US05856525 (9 worldwide citation)

The present invention provides a novel process for making compounds of formula 2a or 2b or pharmaceutically acceptable salts thereof, ##STR1## wherein R.sub.1 is selected from the group consisting of phenyl and phenyl substituted with at least one group selected from NO.sub.2 and halogen;


10
Jiacheng Zhou, Lynette May Oh, Pasquale N Confalone, Hui yin Li, Philip Ma: Synthesis of 1,3,5-trisubstituted pyrazoles. Bristol Myers Squibb Pharma Company, David H Vance, December 11, 2001: US06329527 (5 worldwide citation)

A novel process for making 1,3,5-trisubstituted pyrazoles of the type shown below from appropriate phenyl hydrazines is described.